Telomeres Tell a Tale: Multiple Sclerosis May Accelerate Biological Ageing in Children
A new cross-sectional study in pediatric neurology provides compelling evidence that multiple sclerosis (MS) itself may drive premature biological ageing, even in children. Researchers compared telomere length—a well-established biomarker of cellular ageing—in 300 children with pediatric-onset MS (POMS) against 200 age-similar healthy controls. After adjusting for key sociodemographic and clinical variables, children with POMS had significantly shorter telomeres, suggesting their biological age outpaces their chronological age. This finding strengthens the hypothesis that the inflammatory and neurodegenerative processes in MS contribute directly to accelerated ageing, a concept previously complicated by normal ageing in adult studies.
Study Significance: For pediatric neurologists and specialists managing childhood chronic diseases, this research shifts the paradigm for understanding long-term outcomes. It suggests that monitoring biological ageing markers like telomere length could become a crucial part of assessing disease burden and predicting future disability in pediatric MS, complementing traditional clinical metrics. This insight underscores the need for holistic care strategies that address not just acute relapses but also the potential accelerated ageing trajectory, which could influence decisions on long-term therapeutic intensity and supportive care planning from an early stage.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
